$IBIO News

Last published 1d ago

1d agoIBIOiBio, Inc. - EX-99.1Earnings ReleasesForm 8-K - Current report - Item 2.02 Item 9.01
1d agoIBIOiBio Reports Q1 Fiscal Year 2027 Financial Results and Provides Corporate UpdateGlobeNewswirePresented additional preclinical data supporting IBIO-610’s potential to drive fat selective weight loss in combination with GLP-1 therapy
1w agoIBIOiBio to Participate in Upcoming Investor ConferencesGlobeNewswireSAN DIEGO, Nov. 02, 2026 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ:IBIO), a clinical-stage biotechnology company developing long-acting antibody therapeutics for obesity, cardiometabolic and cardiopulmonary diseases,
4w agoIBIOiBio Highlights Data from a Non-human Primate Study Supporting IBIO-610’s Potential to Preserve Muscle in Combination with GLP-1 TherapyGlobeNewswireIn an eight-week obese NHP study, lean mass made up 6% of weight lost with IBIO-610, an Activin E antibody, plus semaglutide, versus 22% with semaglutide alone iBio expects to start first-in-human trials of IBIO-610
2mo agoIBIOiBio to Participate in the 2026 Wells Fargo Annual Healthcare ConferenceGlobeNewswireSAN DIEGO, Sept. 01, 2026 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ:IBIO), a clinical-stage biotechnology company developing long-acting antibody therapeutics for obesity, cardiometabolic and cardiopulmonary diseases,
2mo agoIBIOiBio Reports Fiscal Year 2026 Financial Results and Provides Corporate UpdateGlobeNewswireSAN DIEGO, Aug. 28, 2026 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ:IBIO), a clinical-stage biotechnology company developing long-acting antibody therapeutics for obesity, cardiometabolic and cardiopulmonary diseases,
3mo agoIBIOiBio Strengthens Clinical Leadership with Appointment of Endocrinologist Molly Carr as Chief Medical OfficerGlobeNewswireSAN DIEGO, Aug. 04, 2026 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ:IBIO), a clinical-stage biotechnology developing long-acting antibody therapeutics for obesity, cardiometabolic and cardiopulmonary diseases, today
4mo agoIBIOiBio Reports Single Dose of IBIO-610 Achieved Near-Complete Active Activin E Inhibition Through Eight Weeks in Obese NHP StudyGlobeNewswireSingle-dose IBIO-610 achieved up to 98% inhibition of active Activin E through eight weeks, supporting a differentiated, long-acting antibody approach When combined with semaglutide, IBIO-610 drove greater visceral and
5mo agoIBIOiBio to Participate in Upcoming Healthcare Investor ConferencesGlobeNewswireSAN DIEGO, June 02, 2026 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ:IBIO) ("iBio" or the "Company"), an AI-driven innovator developing therapies for cardiometabolic, obesity and cardiopulmonary diseases, today announced
5mo agoIBIOiBio Becomes a Clinical-Stage Company with First Participant Dosed in Phase 1 Clinical Trial of IBIO-600 in Adults with ObesityGlobeNewswireIBIO-600 is potentially best-in-class, long-acting anti-myostatin monoclonal antibody designed to preserve muscle and improve body composition First-in-human study of IBIO-600 to evaluate safety, tolerability,
6mo agoIBIOiBio Reports Q3 Fiscal Year 2026 Financial Results and Provides Corporate UpdateGlobeNewswireReceived regulatory clearance to initiate its Phase 1 clinical trial of IBIO-600 in Australia Announced a strategic pipeline expansion into pulmonary hypertension associated with heart failure with preserved ejection
6mo agoIBIOiBio Appoints Distinguished Biotech Leader, Elizabeth Stoner, to its Board of DirectorsGlobeNewswireSAN DIEGO, May 08, 2026 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ:IBIO), an AI-driven innovator developing therapies for cardiometabolic, obesity and cardiopulmonary diseases announced today the appointment of Elizabeth
7mo agoIBIOiBio Received Regulatory Clearance to Initiate Its Phase 1 Clinical Trial of IBIO-600 in AustraliaGlobeNewswireIBIO-600 is a potentially best-in-class, long-acting anti-myostatin monoclonal antibody designed to preserve muscle and improve body compositionFirst participants expected to be dosed in 2Q 2026 SAN DIEGO, April 08,
8mo agoIBIOiBio to Provide an Update on Cardiopulmonary Program Targeting Pulmonary Hypertension Associated with Heart Failure with Preserved Ejection Fraction (PH-HFpEF)GlobeNewswireSAN DIEGO, March 16, 2026 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ:IBIO), an AI-driven innovator developing therapies for cardiometabolic, obesity and cardiopulmonary diseases, today announced the Company will host a
8mo agoIBIOiBio Reports Preclinical Body Composition Data from Obese Non-Human Primates Treated with IBIO-610, a Potential First-in-Class Treatment for Fat-Selective Weight LossGlobeNewswireSAN DIEGO, March 09, 2026 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ:IBIO), an AI-driven innovator developing therapies for cardiometabolic, obesity and cardiopulmonary diseases, today announced new preclinical data from
8mo agoIBIOiBio to Participate in Upcoming Investor ConferencesGlobeNewswireSAN DIEGO, Feb. 24, 2026 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ:IBIO), an AI-driven innovator of precision antibody therapies, today announced that Martin Brenner, DVM, Ph.D., Chief Executive Officer and Chief
9mo agoIBIOiBio Reports Q2 Fiscal Year 2026 Financial Results and Provides Corporate UpdateGlobeNewswireSecured $26 Million in PIPE Financing Led by a Top-Tier Biotech Investor to Advance Preclinical Programs and Extend Cash Runway Progressed Pipeline with New Preclinical Data and Scientific Presentations at Leading
10mo agoIBIOiBio Announces $26 Million Private PlacementGlobeNewswireSAN DIEGO, Jan. 09, 2026 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ:IBIO), an AI-driven innovator of precision antibody therapies, today announced that it has entered into a securities purchase agreement with existing
11mo agoIBIOiBio to Participate in the 8th Annual Evercore Healthcare ConferenceGlobeNewswireSAN DIEGO, Nov. 24, 2025 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ:IBIO), an AI-driven innovator of precision antibody therapies, today announced that it will participate in the 8th Annual Evercore Healthcare Conference,
12mo agoIBIOiBio Reports Q1 Fiscal Year 2026 Financial Results and Provides Corporate UpdateGlobeNewswireStrengthened cash position and extended runway into the fourth quarter of fiscal year 2027 after closing underwritten public offering with up to potentially $100 million of total gross proceeds Presented non-human
1y agoIBIOiBio Unveils New Non-Human Primate Data on IBIO-610, an Activin E Antibody with Strong Therapeutic Potential for Fat-Selective Weight-Loss and Weight MaintenanceGlobeNewswirePreviously reported data showed that in a diet-induced obesity mouse model, IBIO-610 drives fat-selective, GLP-1-synergistic weight loss and prevents weight regain following GLP-1 treatment discontinuation New non-human
1y agoIBIOiBio to Participate in the Guggenheim 2nd Annual Healthcare Innovation ConferenceGlobeNewswireSAN DIEGO, Oct. 23, 2025 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ:IBIO), an AI-driven innovator of precision antibody therapies, today announced that it will participate in the Guggenheim 2nd Annual Healthcare Innovation
1y agoIBIOiBio to Present New Preclinical Data on Its Activin E Antibody at Two Upcoming Scientific Conferences, ObesityWeek® and PEGS Europe 2025GlobeNewswireSAN DIEGO, Oct. 21, 2025 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ:IBIO), an AI-driven innovator of precision antibody therapies, today announced that Cory Schwartz, Ph.D., Director of Research and Early Development at
1y agoIBIOiBio Reports Fiscal Year 2025 Financial Results and Provides Corporate UpdateGlobeNewswireSAN DIEGO, Sept. 05, 2025 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ:IBIO), an AI-driven innovator of precision antibody therapies, today announced its financial results for the fiscal year ended June 30, 2025, and
1y agoIBIOiBio Announces Closing of $50 Million Public OfferingGlobeNewswireTotal gross proceeds of $100 million if all Series G warrants and Series H warrants are exercised for cash Financing was led by Balyasny Asset Management and included participation from Cormorant Asset Management, Adage
1y agoIBIOiBio Announces Pricing of $50 Million Public OfferingGlobeNewswireSAN DIEGO, Aug. 19, 2025 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ:IBIO), an AI-driven innovator of precision antibody therapies, today announced the pricing of an underwritten public offering (the "offering") of (i)
1y agoIBIOiBio Announces Proposed Public OfferingGlobeNewswireSAN DIEGO, Aug. 18, 2025 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ:IBIO), an AI-driven innovator of precision antibody therapies, today announced it has commenced an underwritten public offering (the "offering") of (i)
1y agoIBIOiBio and AstralBio Unveil Obesity Program with Novel Amylin Agonist Antibody Demonstrating Promising In Vivo ResultsGlobeNewswireLead amylin receptor agonist engineered antibody significantly reduced acute food intake in a mouse model of obesity, comparable to the efficacy of a leading amylin peptide agonist Findings support the potential of
1y agoIBIOiBio Presents Next-Generation Obesity and Cardiometabolic Pipeline Candidates on June 24 Conference CallGlobeNewswireReview of promising Myostatin and Activin E antibody data iBio to announce 3rd target in Astral Bio Collaboration Conference call Tuesday, June 24 at 8:30 a.m. ET SAN DIEGO, June 23, 2025 (GLOBE NEWSWIRE) -- iBio,
1y agoIBIOiBio Initiates Non-Human Primate Study of First-in-Class Activin E Antibody Following Positive Preclinical Data Demonstrating Prevention in Weight Regain After GLP-1 TreatmentGlobeNewswireiBio nominates IBIO-610 as development candidate for its first-in-class Activin E antibody New study aims to evaluate the half-life of IBIO-610 in obese, elderly non-human primates (NHP) and assess early signs of
1y agoIBIOiBio's First-in-Class Activin E Antibody Achieves >26% Fat Reduction Without Muscle Loss and Shows Synergy with GLP-1s in Preclinical ModelGlobeNewswireActivin E antibody demonstrates significant decrease in fat in obese mice by reducing visceral fat depots, which are strongly linked to increased risk of cardiovascular and metabolic diseases, resulting in a 26%
1y agoIBIOiBio Reports Fiscal Third Quarter 2025 Financial ResultsGlobeNewswireSAN DIEGO, May 02, 2025 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ:IBIO), today reported financial results for the third quarter ended March 31, 2025, and provided a corporate update on its progress. "During the third
1y agoIBIOiBio Raises $6.2 Million Through Warrant Inducement TransactionGlobeNewswireSAN DIEGO, April 29, 2025 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ:IBIO) ("iBio" or the "Company"), an AI-driven innovator of precision antibody therapies, announces today announced that it has entered into an agreement
1y agoIBIOiBio Expands Cardiometabolic and Obesity Pipeline through Licensing of First-in-Class Antibody Targeting Activin E from AstralBioGlobeNewswireSAN DIEGO, April 22, 2025 (GLOBE NEWSWIRE) -- Bio, Inc. (NASDAQ:IBIO), an AI-driven innovator of precision antibody therapies, today announced a licensing agreement with AstralBio Inc. for a preclinical first-in-class
1y agoIBIOiBio Announces IBIO-600 Non-Human Primate Data Showing Extended Half-Life and Muscle Growth, and Interim In Vivo Results for First-in-Class Activin E Antibody, Advancing Cardiometabolic and Obesity PipelineGlobeNewswireNon-human primate pharmacokinetics data suggests IBIO-600, a potentially best-in-class long-acting anti-myostatin antibody, could have a human half-life as long as 130 days Additional interim in vivo data for a
1y agoIBIOiBio to Begin Trading on the Nasdaq Stock ExchangeGlobeNewswireSAN DIEGO, Feb. 19, 2025 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO), an AI-driven innovator of precision antibody therapies, today announced that iBio's common stock has been approved for listing on the Nasdaq Capital
1y agoIBIOiBio Reports Fiscal Second Quarter 2025 Financial ResultsGlobeNewswireSAN DIEGO, Feb. 10, 2025 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO), today reported financial results for the second quarter ended Dec. 31, 2024, and provided a corporate update on its progress. "In our second fiscal
1y agoONCY ADPT NEO ELEV+2Cutting-Edge Cancer Therapies Lead the Way into a Transformative YearPR NewswireAs 2025 begins, the American Association for Cancer Research (AACR) recently published forecasts from experts showcasing transformative advances in...
1y agoIBIOiBio Announces New Investments from Board Members and OfficersGlobeNewswireSAN DIEGO, Jan. 13, 2025 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA: IBIO), an AI-driven innovator of precision antibody immunotherapies, announced today the closing of a private placement offering with members of its Board
1y agoIBIOiBio Discovers Novel Antibody Targeting Activin E in Collaboration with AstralBioGlobeNewswireSAN DIEGO, Jan. 07, 2025 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA: IBIO), an AI-driven innovator of precision antibody immunotherapies, in collaboration with AstralBio Inc., announced today the development of an antibody
1y agoIBIOiBio Expands Cardiometabolic and Obesity Program with Anti-Myostatin Antibody Discovered Using its Proprietary Platform, In-Licensed from AstralBioGlobeNewswireSAN DIEGO, Jan. 02, 2025 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA: IBIO), an AI-driven innovator of precision antibody immunotherapies, today announced the expansion of its cardiometabolic and obesity treatment
1y agoIBIOiBio Strengthens Board with Appointment of Two New Independent DirectorsGlobeNewswireSAN DIEGO, Nov. 25, 2024 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO), an AI-driven innovator of precision antibody immunotherapies, announced today the appointment of biotech industry veterans David Arkowitz and
1y agoIBIOiBio Reports Fiscal First Quarter 2025 Financial ResultsGlobeNewswireSAN DIEGO, Nov. 12, 2024 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) today reported financial results for the fiscal first quarter ended September 30, 2024 and provided a corporate update on its progress. "In our
2y agoIBIOiBio and AstralBio Provide Update on Myostatin Program for ObesityGlobeNewswireSAN DIEGO, Oct. 10, 2024 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO), an AI-driven innovator of precision antibody immunotherapies, today provided an update on the myostatin program for cardiometabolic disease and
2y agoIBIOiBio Reports Fiscal Year 2024 Financial Results and Provides Corporate UpdateGlobeNewswireSAN DIEGO, Sept. 20, 2024 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO), an AI-driven innovator of precision antibody immunotherapies, today announced its financial results for the fiscal year ended June 30, 2024, and
2y agoIBIOiBio to Participate in Upcoming Investor ConferencesGlobeNewswireSAN DIEGO, Sept. 03, 2024 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO), an AI-driven innovator of precision antibody immunotherapies, announced today that CEO and Chief Scientific Officer, Martin Brenner, DVM, Ph.D.,
2y agoIBIOiBio Expands Executive Leadership Team with Appointment of Kristi Sarno as Senior Vice President of Business DevelopmentGlobeNewswireSAN DIEGO, Aug. 12, 2024 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO), an AI-driven innovator of precision antibody immunotherapies, announced today the appointment of Kristi Sarno as senior vice president, business
2y agoIBIOiBio Closes Sale of Manufacturing Facility in TexasGlobeNewswire– The sale of the facility eliminates $13.2M of secured debt – – Completes iBio's transition to an AI and precision biologics innovation company - SAN DIEGO, June 03, 2024 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO)
2y agoIBIOiBio Reports Fiscal Third Quarter 2024 Financial Results and Provides Corporate UpdateGlobeNewswireStrengthened cash position with investment by healthcare specialist investorsExpanding into cardio-metabolic space through AstralBio collaboration BRYAN, Texas and SAN DIEGO, May 13, 2024 (GLOBE NEWSWIRE) -- iBio,
2y agoIBIOiBio and AstralBio Announce Transformative AI drug discovery Collaboration to Rapidly Develop Novel Antibodies for Obesity and Cardiometabolic DiseasesGlobeNewswire– Leading AI and precision biologics innovators to build a diverse set of novel best-in-class obesity treatments – – iBio to use its patented generative AI/Machine Learning platform to discover, engineer and develop